Gilead Jumps to Highest in 10 Years After Boosting Guidance

Gilead Sciences Inc. lifted its full-year outlook after strong HIV drug sales in the second quarter helped revenue and earnings modestly beat analyst expectations.

The company now expects profit excluding some items will be as much as $8.25 a share this year, up from a prior forecast of as much as $8.10. The drugmaker also raised its guidance for annual product sales by about $100 million.